Over the past 14 years the Australian Centre for HIV & Hepatitis Virology Research (ACH2) has supported translational research in the areas of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) and now human T-Lymphotropic virus type-1 (HTLV-1).
ACH2 is seeking expressions of interest (EoI) in applied research from qualified scientists to fund research projects in 2018 aimed at:
- developing vaccine candidates for HIV, HCV or HTLV-1;
- developing preventatives such as HIV microbicides and pre-exposure prophylaxis (PrEP);
- cure and treatment interventions for HIV, HBV, or HTLV-1;
- novel diagnostics and prognostics for HIV, HBV, HCV, HTLV-1 or hepatitis B/C/HIV/HTLV-1 co-infection;
- molecular tools for tracking epidemics caused by these viruses; and
- development of new tests for supporting vaccine and antiviral trials.
These grants are intended to complement and translate basic research in the virology and immunology of HIV, HBV, HCV and HTLV-1, usually initially funded by other granting bodies.
Funding & Duration
Funding is available from 1 January 2018 to 31 December 2018 for grants up to $110,000.
Basic research is not eligible, and grants aimed at development of new direct-acting antivirals against HCV are not eligible.
Chief investigators (CIs) must be equivalent to NHMRC PSP 4, usually with independent funding.
Submission Requirements & Due Date
- Expressions of Interest (EoI) must be submitted for internal review by 15 November 2017
- Please complete your RFR through ResearchMaster. When prompted to Select Fund Scheme use Fund Scheme code ORG105111
- Submit an Application to Research Services for Review